Industry News

• Smoking linked to higher risk of peripheral artery disease in African-Americans  African-Americans who smoke appear to be at greater risk for peripheral artery disease, or PAD, new research has found. Additionally, the findings suggest that smoking intensity – how many cigarettes a day and for how many years – also affects the likelihood of getting the disease.
  January 23, 2019  
• Blood test shows promise for early detection of severe lung-transplant rejection  Researchers have developed a simple blood test that can detect when a newly transplanted lung is being rejected by a patient, even when no outward signs of the rejection are evident. The test could make it possible for doctors to intervene faster to prevent chronic rejection.
  January 23, 2019  
• Neovasc announces peer reviewed publication in JACC  Neovasc announced the Journal of the American College of Cardiology: Cardiovascular Interventions published a peer reviewed article on the use of dipyridamole stress perfusion cardiac magnetic resonance to assess the performance of its Neovasc Reducer™ for treatment of refractory angina.
  January 23, 2019  
• Rexahn announces pricing of public offering of common stock and warrants  Rexahn Pharmaceuticals announced pricing of an underwritten public offering of 10,750,000 shares of its common stock and warrants to purchase up to 10,750,000 shares of its common stock. Each share of common stock is being sold together in a fixed combination with a warrant.
  January 23, 2019  
• Rigel Pharmaceuticals enters collaboration and license agreement with Grifols  Rigel Pharmaceuticals announced it has entered into an exclusive license and supply agreement with Spain-based Grifols to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey.
  January 23, 2019  
• Henry Schein to expand medical group with acquisition of North American Rescue  Henry Schein announced the signing of a definitive agreement to acquire approximately 93 percent of North American Rescue, the leading provider of survivability and casualty-care medical products to the defense and public-safety markets. Financial terms were not disclosed.
  January 23, 2019  
• Bermekimab successfully treats Hidradenitis Suppurativa, including pain reduction  XBiotech announced the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with moderate to severe Hidradenitis Suppurativa. Primary and key secondary endpoints were met in this study with significant, differentiating findings.
  January 23, 2019  
• Calyxt doubles 2018 high oleic soybean acres  Calyxt announced it has contracted over 34,000 acres of its High Oleic Soybean with more than 100 farmers in the upper Midwest region including South Dakota, Minnesota, Iowa and Nebraska. The company has doubled the 17,000 acres planted in 2018.
  January 23, 2019  
• Abbott reports 2018 results and issues strong 2019 forecast  Abbott reported full-year 2018 worldwide sales of $30.6 billion increased 11.6 percent on a reported basis. Reported diluted EPS from continuing operations under GAAP was $1.31 in the full year 2018.
  January 23, 2019  
• Bellerophon announces pricing of $7 million public offering of common stock  Bellerophon announced pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share. The Company also granted underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock.
  January 23, 2019  

   (next 10 articles)